Clinical Trial: NCT06383338
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
Status:
RECRUITINGPhase:
Phase 1| Lead Sponsor: | Murdoch Childrens Research Institute |
| Information Provided By: | Murdoch Childrens Research Institute |
| Last Update Posted: | 2026-08-27 |
Study Overview
Brief Summary
PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers.
The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications.
The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.
Official Title
Conditions
Intervention / Treatment
- Drug: Omeprazole
- Drug: Dextromethorphan
Other Study ID Numbers
- PEGASUS 2023/ETH01954
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Murdoch Childrens Research Institute |
| Information Provided By: | Murdoch Childrens Research Institute |
| Last Update Posted: | 2026-08-27 |
Study Overview
Brief Summary
PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers.
The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications.
The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.
Official Title
Conditions
Intervention / Treatment
- Drug: Omeprazole
- Drug: Dextromethorphan
Other Study ID Numbers
- PEGASUS 2023/ETH01954